In phase III trial, Libtayo demonstrates improved OS in advanced cervical cancer

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

For over a month since President Trump announced his intent to impose aggressive new tariffs on America’s friends and foes alike, lobbyists for hospitals, medical societies, and makers of branded and generic drugs have been trying to convince him to rethink.

March 21, 2025

Vol.51 No.11

By Claire Marie Porter and Jacquelyn Cobb

Guest Editorial

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment.

March 21, 2025

Vol.51 No.11

By Shannon McWeeney and Sorena Nadaf-Rahrov

White House

Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism

Columbia’s Herbert Irving Cancer Center is 52 streets, 2.6 miles, and five subway stops away from the university’s main campus and the pro-Palestinian protests that have been taking place there.

Rathmell: We need a “March Madness” for cancer research
“Cancer is a tremendously challenging tournament, but we are in it to win”

Although this column is running in The Cancer Letter, where we turn for timely insights and information relevant to the cancer community, I suspect that a lot of our readers are watching college basketball this week.

March 21, 2025

Vol.51 No.11

By W. Kimryn Rathmell

Guest Editorial

Health innovation and health equity: Ensuring technologies advance resilience, justice, and compassionate care

Technological innovations are often hailed as transformative tools capable of revolutionizing healthcare. From gene editing for conditions like sickle cell disease to AI predicting hospital readmissions, to telemedicine expanding healthcare access, these advancements have the potential to change the way we treat diseases.

March 21, 2025

Vol.51 No.11

By Jamillah Hoy-Rosas

Targeting the thymus to rejuvenate immune function

The thymus gland, in many ways, remains a mystery. The thymic regeneration division of the laboratory of Marcel van den Brink, president of City of Hope Los Angeles and City of Hope National Medical Center, is trying to tease out its secrets.

March 21, 2025

Vol.51 No.11

By City of Hope

In phase III trial, Libtayo demonstrates improved OS in advanced cervical cancer

YOU MAY BE INTERESTED IN

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism

Rathmell: We need a “March Madness” for cancer research
“Cancer is a tremendously challenging tournament, but we are in it to win”

Health innovation and health equity: Ensuring technologies advance resilience, justice, and compassionate care

Targeting the thymus to rejuvenate immune function

Renew today!

Subscriber content

Never miss an issue!

Login

In phase III trial, Libtayo demonstrates improved OS in advanced cervical cancer

YOU MAY BE INTERESTED IN

Trump’s tariffs will likely affect cancer drugs and devices—and may deepen drug shortages

Caught in the crossfire: The critical threats facing cancer centers, research, and patient care

Columbia’s cancer center becomes collateral damage in Trump’s war on antisemitism

Rathmell: We need a “March Madness” for cancer research“Cancer is a tremendously challenging tournament, but we are in it to win”

Health innovation and health equity: Ensuring technologies advance resilience, justice, and compassionate care

Targeting the thymus to rejuvenate immune function

Never miss an issue!

Login

Rathmell: We need a “March Madness” for cancer research
“Cancer is a tremendously challenging tournament, but we are in it to win”